key: cord-0336037-5ki4evgi
authors: Ramanathan, M.; Murugesan, K.; Yang, L. M.; Costales, C.; Bulterys, P. L.; Schroers-Martin, J.; Alizadeh, A. A.; Boyd, S. D.; Brown, J. M.; Nadeau, K. C.; Nadimpalli, S. S.; Wang, A. X.; Busque, S.; Pinsky, B. A.; Banaei, N.
title: Cell-Mediated and Humoral Immune Response to 2-Dose SARS-CoV2 mRNA vaccination in Immunocompromised patient population
date: 2021-07-23
journal: nan
DOI: 10.1101/2021.07.21.21260921
sha: e9c6b3e2380b400fccfd4b80f350cc187ac7bab2
doc_id: 336037
cord_uid: 5ki4evgi

Characterization of cell-mediated and humoral immune responses to SARS-CoV2 mRNA vaccine has implications for protective immunity in immunocompromised patients. However, studies have demonstrated poor humoral response to SARS-CoV2 mRNA vaccine in immunocompromised patients and data on cellular immune response are currently lacking. Here we compared immune response after 2-dose vaccination in 100 immunocompromised patients (solid organ transplant recipients, hematologic malignancy, autoimmune condition, and primary immunodeficiency) and 16 immunocompetent healthy healthcare workers. We find that 100% (CI=80.6-100%) of immunocompetent individuals show positive cell-mediated and humoral immune response post vaccination while only 50% (CI=40.4-59.6%) of immunocompromised patients show humoral immune response and 69% (CI=59.4-77.2%) have a positive cell-mediated immune response. 21% of immunocompromised patients have no humoral immune response or cell-mediated immune response and thus are likely vulnerable to SARS-CoV2 infection. Monitoring of immune response in immunocompromised populations, particularly in high-risk immunocompromised patients (solid organ transplant recipients, patients with severe autoimmunity, and those [≥]50 years), with clinical IGRA and serological assay after vaccination may identify patients who may benefit from revaccination or prophylactic monoclonal antibody therapy to prevent COVID-19 in this patient population

is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint One in 25 Americans are estimated to be immunocompromised 1 Here, we compared cell-mediated and humoral immune responses to SARS-CoV-2 mRNA vaccination in immunocompromised patients and immunocompetent controls. Clinically orderable laboratory-developed interferon-γ release assay (IGRA) was performed to measure and qualitatively interpret T-cell response to SARS-CoV2 antigens. Humoral response was evaluated using a commercial ELISA assay measuring IgG for the SARS-CoV-2 spike S1 domain. Figure 1A ). However, there was no significant difference in median interferon-γ . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint response in controls when compared with immunocompromised patients (1.29 IU/mL vs 1.23 IU/mL; p=0.2) ( Figure 1B ). All 16 (100%, CI=80.6-100%) controls had a positive qualitative antibody result compared to 50% (CI=40.4-59.6%) positivity rate in immunocompromised patients ( Figure 1C ). Immunocompetent controls had higher median antibody IgG levels compared to immunocompromised patients (12 vs 2.42 OD ratio, p<0.0001) ( Figure 1D ). In 29% of immunocompromised patients, cell-mediated response was the only positive immune is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint COVID-19 in vaccinated, immunocompromised patients with cell-mediated immune response alone. In contrast to immunocompetent healthcare workers, in whom 100% had positive cellular and humoral immune response, this study revealed that a significant fraction (21%) of immunocompromised patients mount no cellular or humoral response after vaccination and likely remain susceptible to infection with ancestral strains or emerging variants of SARS-CoV2.

Monitoring of immune response in immunocompromised populations, particularly in high-risk immunocompromised patients (solid organ transplant recipients, patients with severe autoimmunity, and those ≥50 years), with clinical IGRA and serological assay after vaccination may identify patients who may benefit from revaccination 5 or prophylactic monoclonal antibody therapy to prevent COVID-19 in this patient population.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint Percentage of patients with positive Anti-SARS-CoV2 S1 IgG ELISA result. (D) Anti-SARS-CoV2 S1 IgG optical density (OD) ratio from ELISA performed in immunocompetent and immunocompromised patients.

Results for immunocompromised subgroups are also shown. Dotted lines represent the assay cutoffs (0.35 IU/mL for IGRA and 2.5 optical density ratio for IgG). Long solid lines show median, short solid lines show 95% confidence interval. ns, not significant and ****, p<0.0001 by Mann-Whitney U test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint cutoffs (0.35 IU/mL for IGRA and 2.5 optical density ratio for IgG). Solid lines show median. ns, not significant by Mann-Whitney U test. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint (A) Interferon-γ response with interferon-γ release assay. (B) IgG levels with Anti-SARS-CoV-2 S1 IgG ELISA. Tests were performed in immunocompromised patients (n=100) comparing median age below 50 (n=36) with 50 or above (n=64). Dotted lines represent the assay cutoffs (0.35 IU/mL for IGRA and 2.5 optical density ratio for IgG). Solid lines show median. ns, not significant and ***, p<0.001 by Mann-Whitney U test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint

Percentage of patients with negative SARS-CoV2 Interferon-γ release assay and negative Anti-SARS-CoV2 S1 IgG ELISA results after 2 doses of SARS-CoV2 mRNA vaccination.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. negative if antigen-nil <0.35 and mitogen-nil ≥0.5 IU/mL, and indeterminate if nil >8 IU/mL or antigen-nil <0.35 and mitogen-nil <0.5 IU/mL. All values higher than 10 IU/mL were adjusted to 10 IU/mL to reflect the linear range of assay.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint SARS-CoV-2 Spike S1 IgG serology was performed by semi-quantitative ELISA (EUROIMMUN, Lübeck, Germany) according to the manufacturer's instructions. Briefly, 1:100 diluted serum samples from vaccinees were added to the antigen pre-coated microplate followed by the addition of anti-human IgG conjugate, chromogenic substrate and stopping solution. The optical density (OD) was measured at 450nm. Results were evaluated by calculating the ratio of the optical density (OD) of the sample over the OD of a calibrator provided by the manufacturer.

Assay cutoff values were defined as follows: <2.5 negative, ≥2.5 positive 2 . All values higher than OD 12 were adjusted to 12 to reflect the linear range of assay.

GraphPad Prism version 9.0 (GraphPad Software, San Diego, California, USA) software was used to visualize data and Mann-Whitney U test was performed to compare cellular and humoral response in immunocompetent and immunocompromised patients.

Prevalence of immunosuppression among us adults

Antibody response to 2-dose sars-cov-2 mrna vaccine series in solid organ transplant recipients

SARS-CoV-2 evolution during treatment of chronic infection

Cellular immune correlates of protection against symptomatic pandemic influenza

Three doses of an mrna covid-19 vaccine in solid-organ transplant recipients

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response

Validation of a commercially available SARS-CoV-2

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

We thank all study participants, providers and nursing staff caring for immunocompromised patients evaluated in this study.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260921 doi: medRxiv preprint